1. Home
  2. TGNA vs VRDN Comparison

TGNA vs VRDN Comparison

Compare TGNA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TEGNA Inc

TGNA

TEGNA Inc

HOLD

Current Price

$18.91

Market Cap

3.0B

Sector

Industrials

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$31.81

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGNA
VRDN
Founded
1906
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TGNA
VRDN
Price
$18.91
$31.81
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$20.00
$41.17
AVG Volume (30 Days)
1.1M
1.4M
Earning Date
02-26-2026
02-26-2026
Dividend Yield
2.65%
N/A
EPS Growth
N/A
N/A
EPS
2.10
N/A
Revenue
$2,876,414,000.00
$70,789,000.00
Revenue This Year
N/A
$26,080.80
Revenue Next Year
$11.10
$3.26
P/E Ratio
$8.98
N/A
Revenue Growth
N/A
23340.07
52 Week Low
$14.87
$9.90
52 Week High
$21.35
$34.29

Technical Indicators

Market Signals
Indicator
TGNA
VRDN
Relative Strength Index (RSI) 41.41 47.48
Support Level $18.80 $31.26
Resistance Level $19.00 $34.20
Average True Range (ATR) 0.23 1.36
MACD 0.02 -0.04
Stochastic Oscillator 26.34 21.73

Price Performance

Historical Comparison
TGNA
VRDN

About TGNA TEGNA Inc

Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: